PI3K and PARP Inhibitors in HR+ Metastatic Breast Cancer
15 Mga view
• 07/03/23
0
0
I-embed
administrator
Mga subscriber
Joyce A. O’Shaughnessy, MD, and Andrew D. Seidman, MD, evaluate treatment options outside of CDK4/6 inhibition, such as PI3-kinase or poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors, for patients with hormone-receptor positive metastatic breast cancer.
Magpakita ng higit pa
Mga Komento sa Facebook
SORT BY-
Mga Nangungunang Komento
-
Pinakabagong komento